Primary Biliary Cholangitis: advances in management and treatment of the disease

Pietro Invernizzi, Annarosa Floreani, Marco Carbone, Marco Marzioni, Antonio Craxi, Luigi Muratori, Umberto Vespasiani Gentilucci, Ivan Gardini, Antonio Gasbarrini, Paola Kruger, Francesco Saverio Mennini, Virginia Ronco, Elena Lanati, Pier Luigi Canonico, Domenico Alvaro

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Primary Biliary Cholangitis, previously known as Primary Biliary Cirrhosis, is a rare disease, which mainly affects women in their fifth to seventh decades of life. It is a chronic autoimmune disease characterized by a progressive damage of interlobular bile ducts leading to ductopenia, chronic cholestasis and bile acids retention. Even if the disease usually presents a long asymptomatic phase and a slow progression, in many patients it may progress faster toward cirrhosis and its complications. The 10 year mortality is greater than in diseases such as human immunodeficiency virus/Hepatitis C Virus coinfection and breast cancer. Ursodeoxycholic acid is the only treatment available today, but even if effective in counteracting the disease progression for the majority of patients, in approximately 40% is not able to decrease effectively the alkaline phosphatase, a surrogate marker of disease activity. Recently, obeticholic acid received the European Medicines Agency conditional approval, as add on treatment in patients non responders or intolerant to ursodeoxycholic acid. The present paper illustrates the opinion of a working group, composed by clinical pharmacologists, gastroenterologists/hepatologists with specific expertise on Primary Biliary Cholangitis and patient associations, on the state of the art and future perspectives of the disease management. The agreement on the document was reached through an Expert Meeting.

Original languageEnglish (US)
Pages (from-to)841-846
Number of pages6
JournalDigestive and Liver Disease
Volume49
Issue number8
DOIs
StatePublished - Aug 1 2017
Externally publishedYes

Fingerprint

Cholangitis
Disease Management
Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Cholestasis
Therapeutics
Rare Diseases
Bile Ducts
Bile Acids and Salts
Coinfection
Hepacivirus
Autoimmune Diseases
Alkaline Phosphatase
Disease Progression
Fibrosis
Chronic Disease
Biomarkers
HIV
Breast Neoplasms
Mortality

Keywords

  • Alkaline phosphatase
  • Budesonide
  • Fibrates
  • Obeticholic acid
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Invernizzi, P., Floreani, A., Carbone, M., Marzioni, M., Craxi, A., Muratori, L., ... Alvaro, D. (2017). Primary Biliary Cholangitis: advances in management and treatment of the disease. Digestive and Liver Disease, 49(8), 841-846. https://doi.org/10.1016/j.dld.2017.05.001

Primary Biliary Cholangitis : advances in management and treatment of the disease. / Invernizzi, Pietro; Floreani, Annarosa; Carbone, Marco; Marzioni, Marco; Craxi, Antonio; Muratori, Luigi; Vespasiani Gentilucci, Umberto; Gardini, Ivan; Gasbarrini, Antonio; Kruger, Paola; Mennini, Francesco Saverio; Ronco, Virginia; Lanati, Elena; Canonico, Pier Luigi; Alvaro, Domenico.

In: Digestive and Liver Disease, Vol. 49, No. 8, 01.08.2017, p. 841-846.

Research output: Contribution to journalArticle

Invernizzi, P, Floreani, A, Carbone, M, Marzioni, M, Craxi, A, Muratori, L, Vespasiani Gentilucci, U, Gardini, I, Gasbarrini, A, Kruger, P, Mennini, FS, Ronco, V, Lanati, E, Canonico, PL & Alvaro, D 2017, 'Primary Biliary Cholangitis: advances in management and treatment of the disease', Digestive and Liver Disease, vol. 49, no. 8, pp. 841-846. https://doi.org/10.1016/j.dld.2017.05.001
Invernizzi P, Floreani A, Carbone M, Marzioni M, Craxi A, Muratori L et al. Primary Biliary Cholangitis: advances in management and treatment of the disease. Digestive and Liver Disease. 2017 Aug 1;49(8):841-846. https://doi.org/10.1016/j.dld.2017.05.001
Invernizzi, Pietro ; Floreani, Annarosa ; Carbone, Marco ; Marzioni, Marco ; Craxi, Antonio ; Muratori, Luigi ; Vespasiani Gentilucci, Umberto ; Gardini, Ivan ; Gasbarrini, Antonio ; Kruger, Paola ; Mennini, Francesco Saverio ; Ronco, Virginia ; Lanati, Elena ; Canonico, Pier Luigi ; Alvaro, Domenico. / Primary Biliary Cholangitis : advances in management and treatment of the disease. In: Digestive and Liver Disease. 2017 ; Vol. 49, No. 8. pp. 841-846.
@article{d63d573a01674b109cbde2148b7a790b,
title = "Primary Biliary Cholangitis: advances in management and treatment of the disease",
abstract = "Primary Biliary Cholangitis, previously known as Primary Biliary Cirrhosis, is a rare disease, which mainly affects women in their fifth to seventh decades of life. It is a chronic autoimmune disease characterized by a progressive damage of interlobular bile ducts leading to ductopenia, chronic cholestasis and bile acids retention. Even if the disease usually presents a long asymptomatic phase and a slow progression, in many patients it may progress faster toward cirrhosis and its complications. The 10 year mortality is greater than in diseases such as human immunodeficiency virus/Hepatitis C Virus coinfection and breast cancer. Ursodeoxycholic acid is the only treatment available today, but even if effective in counteracting the disease progression for the majority of patients, in approximately 40{\%} is not able to decrease effectively the alkaline phosphatase, a surrogate marker of disease activity. Recently, obeticholic acid received the European Medicines Agency conditional approval, as add on treatment in patients non responders or intolerant to ursodeoxycholic acid. The present paper illustrates the opinion of a working group, composed by clinical pharmacologists, gastroenterologists/hepatologists with specific expertise on Primary Biliary Cholangitis and patient associations, on the state of the art and future perspectives of the disease management. The agreement on the document was reached through an Expert Meeting.",
keywords = "Alkaline phosphatase, Budesonide, Fibrates, Obeticholic acid, Ursodeoxycholic acid",
author = "Pietro Invernizzi and Annarosa Floreani and Marco Carbone and Marco Marzioni and Antonio Craxi and Luigi Muratori and {Vespasiani Gentilucci}, Umberto and Ivan Gardini and Antonio Gasbarrini and Paola Kruger and Mennini, {Francesco Saverio} and Virginia Ronco and Elena Lanati and Canonico, {Pier Luigi} and Domenico Alvaro",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.dld.2017.05.001",
language = "English (US)",
volume = "49",
pages = "841--846",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Primary Biliary Cholangitis

T2 - advances in management and treatment of the disease

AU - Invernizzi, Pietro

AU - Floreani, Annarosa

AU - Carbone, Marco

AU - Marzioni, Marco

AU - Craxi, Antonio

AU - Muratori, Luigi

AU - Vespasiani Gentilucci, Umberto

AU - Gardini, Ivan

AU - Gasbarrini, Antonio

AU - Kruger, Paola

AU - Mennini, Francesco Saverio

AU - Ronco, Virginia

AU - Lanati, Elena

AU - Canonico, Pier Luigi

AU - Alvaro, Domenico

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Primary Biliary Cholangitis, previously known as Primary Biliary Cirrhosis, is a rare disease, which mainly affects women in their fifth to seventh decades of life. It is a chronic autoimmune disease characterized by a progressive damage of interlobular bile ducts leading to ductopenia, chronic cholestasis and bile acids retention. Even if the disease usually presents a long asymptomatic phase and a slow progression, in many patients it may progress faster toward cirrhosis and its complications. The 10 year mortality is greater than in diseases such as human immunodeficiency virus/Hepatitis C Virus coinfection and breast cancer. Ursodeoxycholic acid is the only treatment available today, but even if effective in counteracting the disease progression for the majority of patients, in approximately 40% is not able to decrease effectively the alkaline phosphatase, a surrogate marker of disease activity. Recently, obeticholic acid received the European Medicines Agency conditional approval, as add on treatment in patients non responders or intolerant to ursodeoxycholic acid. The present paper illustrates the opinion of a working group, composed by clinical pharmacologists, gastroenterologists/hepatologists with specific expertise on Primary Biliary Cholangitis and patient associations, on the state of the art and future perspectives of the disease management. The agreement on the document was reached through an Expert Meeting.

AB - Primary Biliary Cholangitis, previously known as Primary Biliary Cirrhosis, is a rare disease, which mainly affects women in their fifth to seventh decades of life. It is a chronic autoimmune disease characterized by a progressive damage of interlobular bile ducts leading to ductopenia, chronic cholestasis and bile acids retention. Even if the disease usually presents a long asymptomatic phase and a slow progression, in many patients it may progress faster toward cirrhosis and its complications. The 10 year mortality is greater than in diseases such as human immunodeficiency virus/Hepatitis C Virus coinfection and breast cancer. Ursodeoxycholic acid is the only treatment available today, but even if effective in counteracting the disease progression for the majority of patients, in approximately 40% is not able to decrease effectively the alkaline phosphatase, a surrogate marker of disease activity. Recently, obeticholic acid received the European Medicines Agency conditional approval, as add on treatment in patients non responders or intolerant to ursodeoxycholic acid. The present paper illustrates the opinion of a working group, composed by clinical pharmacologists, gastroenterologists/hepatologists with specific expertise on Primary Biliary Cholangitis and patient associations, on the state of the art and future perspectives of the disease management. The agreement on the document was reached through an Expert Meeting.

KW - Alkaline phosphatase

KW - Budesonide

KW - Fibrates

KW - Obeticholic acid

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=85019847570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019847570&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2017.05.001

DO - 10.1016/j.dld.2017.05.001

M3 - Article

AN - SCOPUS:85019847570

VL - 49

SP - 841

EP - 846

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 8

ER -